Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Columbus, Ohio

Cancer biologic therapy trials in Columbus, OH

65 cancer biologic therapy studies are recruiting participants at sites in Columbus as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Columbus at a glance

  • 65 studies are recruiting at a site in Columbus.
  • By phase: Early Phase 1 (1), Phase 1 (14), Phase 1/2 (8), Phase 2 (20), Phase 2/3 (2), Phase 3 (20).
  • By sponsor: university, hospital or other (29), government (21), industry (15).
  • By research area: Lymphoma (26), Lung Cancer (20), Breast Cancer (8), Melanoma (8), Prostate Cancer (2), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Columbus

Basic details from each study's public record (the 30 most recently updated of 65). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT03606967 · updated
  2. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT05422794 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
    Registry record
    NCT05564377 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
    Registry record
    NCT06058377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Columbus, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Columbus

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Study site
    Clinical Study Sites
    Registry record
    NCT06767514 · updated
  3. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT06287775 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Mount Carmel East Hospital · Mount Carmel Health Center West · The Mark H Zangmeister Center
    Registry record
    NCT04267848 · updated
  5. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Ohio State University Comprehensive Cancer Center · The Mark H Zangmeister Center
    Registry record
    NCT06096844 · updated
  6. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
    Registry record
    NCT04181060 · updated
  7. KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015)
    Registry record
    NCT04165070 · updated
  8. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (Adults and Pediatrics)
    Registry record
    NCT03394365 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Columbus, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Columbus

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Columbus Oncology and Hematology Associates Inc · Doctors Hospital · Grant Medical Center
    Registry record
    NCT03866382 · updated
  2. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    The Ohio State University
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Columbus, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Columbus

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Ohio State University
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Columbus, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Columbus

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT03739814 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT06337318 · updated
  3. Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    John Reneau
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT04848064 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Nationwide Children's Hospital
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Nationwide Children's Hospital
    Registry record
    NCT05675410 · updated
  7. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT07003295 · updated
  8. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT06649812 · updated
  9. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Study site
    The Ohio State University Comprehensive Cancer Center
    Registry record
    NCT07015242 · updated
  10. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT03150693 · updated
  11. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT05976763 · updated
  12. A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AIDS Malignancy Consortium
    Study site
    The Ohio State University
    Registry record
    NCT04139304 · updated
  13. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Nationwide Children's Hospital
    Registry record
    NCT06124157 · updated
  14. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    • Phase 1/2
    • Ages 13 to 90
    • All sexes
    Sponsor
    Vironexis Biotherapeutics Inc.
    Study site
    The Ohio State University Wexner Medical Center
    Registry record
    NCT06533579 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Columbus, OH on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Columbus

  1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Columbus, OH on ClinicalTrials.gov.

Ask about studies near Columbus

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call